한국인 류마티스관절염 환자에서 항 TNF 제제의 지속성에 관한 연구 (Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients)

서지정보

· 발행기관 : 대한류마티스학회
· 수록지 정보 : 대한류마티스학회지 / 18권 / 3호 / 161 ~ 167페이지
· 저자명 : 조수경, 성윤경, 최찬범, 엄완식, 김태환, 전재범, 유대현, 배상철

초록

Objective. To estimate drug persistency and the safety of TNF blocker in Korean patients with rheumatoid arthritis.
Methods. Data were extracted from medical records of rheumatoid arthritis patients who had treated with TNF blocker or are currently using TNF blocker at Hanyang University Hospital for Rheumatic Diseases from December 2000 to November 2009 (REtrospective study for Safety and Efficacy of Anti-RA treatment with biologiCs, RESEARCh). Comprehensive chart reviews were undertaken on all patients and data on drug usages and response of TNF blocker was collected at initiation, 3 months and the time of data collection. Persistency with treatment was examined using life-table analysis and multivariate Cox proportional hazard models were developed to examine potential predictors of discontinuation of TNF blocker.
Result. A total of 268 patients were enrolled in this retrospective study. Among them 180 patients were included in the analysis of drug persistency. The 1-year and 5-year drug persistency of TNF blocker was 74% and 46%, respectively. Concomitant use of methotrexate (hazard ratio 0.46, 95% CI 0.27-0.80) was associated with higher persistence. Comparing to etanercept, adalimumab is an independent risk factor for discontinuation (hazard ratio 2.63, 95% CI 1.43-4.84).
Conclusion. Five-year drug persistency of TNF blocker was 46% and concomitant use of methotrexate is associated with higher persistence.

영어초록

Objective. To estimate drug persistency and the safety of TNF blocker in Korean patients with rheumatoid arthritis.
Methods. Data were extracted from medical records of rheumatoid arthritis patients who had treated with TNF blocker or are currently using TNF blocker at Hanyang University Hospital for Rheumatic Diseases from December 2000 to November 2009 (REtrospective study for Safety and Efficacy of Anti-RA treatment with biologiCs, RESEARCh). Comprehensive chart reviews were undertaken on all patients and data on drug usages and response of TNF blocker was collected at initiation, 3 months and the time of data collection. Persistency with treatment was examined using life-table analysis and multivariate Cox proportional hazard models were developed to examine potential predictors of discontinuation of TNF blocker.
Result. A total of 268 patients were enrolled in this retrospective study. Among them 180 patients were included in the analysis of drug persistency. The 1-year and 5-year drug persistency of TNF blocker was 74% and 46%, respectively. Concomitant use of methotrexate (hazard ratio 0.46, 95% CI 0.27-0.80) was associated with higher persistence. Comparing to etanercept, adalimumab is an independent risk factor for discontinuation (hazard ratio 2.63, 95% CI 1.43-4.84).
Conclusion. Five-year drug persistency of TNF blocker was 46% and concomitant use of methotrexate is associated with higher persistence.

참고자료

· 없음